Wynn Resorts: Wynn Macau traded 3.0% lower in Hong Kong after Macau Daily Times reported language in 10-K suggests increased junket competition could result in WYNN paying higher commissions
US WYNN $127.27 tasemel ~1% tõusus
AMLN
Amylin Pharma, Eli Lilly (LLY) and Alkermes (ALKS) provide top-line results from DURATION-6, head-to-head study; patients receiving BYDUREON experienced a reduction in A1C of 1.3 percentage points from baseline, compared to a reduction of 1.5 percentage points for Victoza. (15.01 ) AMLN, LLY and ALKS, the 3 cos that are working together to develop BYDUREON announce top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON to daily Victoza. Results showed that patients receiving BYDUREON experienced a reduction in A1C of 1.3 percentage points from baseline, compared to a reduction of 1.5 percentage points for Victoza. BYDUREON did not meet the pre-specified primary endpoint of non-inferiority to Victoza. Gastrointestinal adverse events occurred more frequently among Victoza patients (nausea reported among 20% of patients, vomiting 11%, diarrhea 13%) compared with BYDUREON patients (nausea 9%, vomiting 4%, diarrhea 6%). Injection site nodule occurred more frequently among BYDUREON users (10%) compared with Victoza users (1%). There were no major hypoglycemia events in either treatment group.
Amylin Pharma, Eli Lilly (LLY) and Alkermes (ALKS) provide top-line results from DURATION-6, head-to-head study; patients receiving BYDUREON experienced a reduction in A1C of 1.3 percentage points from baseline, compared to a reduction of 1.5 percentage points for Victoza. (15.01 ) AMLN, LLY and ALKS, the 3 cos that are working together to develop BYDUREON announce top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON to daily Victoza. Results showed that patients receiving BYDUREON experienced a reduction in A1C of 1.3 percentage points from baseline, compared to a reduction of 1.5 percentage points for Victoza. BYDUREON did not meet the pre-specified primary endpoint of non-inferiority to Victoza. Gastrointestinal adverse events occurred more frequently among Victoza patients (nausea reported among 20% of patients, vomiting 11%, diarrhea 13%) compared with BYDUREON patients (nausea 9%, vomiting 4%, diarrhea 6%). Injection site nodule occurred more frequently among BYDUREON users (10%) compared with Victoza users (1%). There were no major hypoglycemia events in either treatment group.
Marek9, siin põhjus:
A long-awaited experimental diabetes medicine from Eli Lilly & Co (LLY.N) and Amylin Pharmaceuticals Inc (AMLN.O) that patients need to inject only once a week failed to match up to a rival treatment taken daily, sending Amylin shares tumbling 25 percent. (link)
A long-awaited experimental diabetes medicine from Eli Lilly & Co (LLY.N) and Amylin Pharmaceuticals Inc (AMLN.O) that patients need to inject only once a week failed to match up to a rival treatment taken daily, sending Amylin shares tumbling 25 percent. (link)
RIMM-l võttis täna liikuma saamine aega. Aktsia avanes $66,84 pealt ehk 1,6% plusspoolel ning jäi ca tunniks liikuma $66,70-$67,20 vahemikku, siis aga tegi järsu liikumise üles, käies ära ka üle $68 taseme. Hetkel kaupleb RIMM $67,80 kandis ehk 3% plusspoolel.
The Fed purchased $7.24 bln of 2018-2021 maturities through Permanent Open Market Operations as dealers looked to put back $21.66 bln
President Obama makes statment on Libya; says time for Gaddafi to leave